AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01253603
Drug: Placebo to QAW039 capsules once daily for 28 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00749190
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00710385
Drug: Low Bup/Nal Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/Naloxone 4/1 mg, 8/2 mg
Trial: NCT00710385
Drug: High Bup/Nal Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/Naloxone 8/2 mg, 16/4 mg
Trial: NCT00710385
Drug: Placebo (PCB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control administration
Trial: NCT02839694
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally twice a day every day for while on DAC-THU therapy
Trial: NCT01455220
Drug: Tysabri ® (Natalizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, monthly
Trial: NCT01175395
Drug: IBI-20089/Lucentis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
Trial: NCT02142036
Drug: EMA-approved ATI based targeted therapy
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
Trial: NCT00633984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
Trial: NCT00716716
Drug: rFIXFc
RxNorm normalized name: rFIXFc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As specified in the treatment arm
Trial: NCT02272790
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
Trial: NCT00332202
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT00702143
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection, 370MBq (10mCi), single dose
Trial: NCT04439890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03871491
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
Trial: NCT03871491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical appearing placebo, administered as a single oral dose directly after randomization.
Trial: NCT02920125
Drug: SUVED
RxNorm normalized name: Suvedolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
Trial: NCT02429999
Drug: Letrezole plus FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
Trial: NCT02429999
Drug: Standard protocol for induction of ovulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
Trial: NCT01822561
Drug: Eplerenone 50mg
RxNorm normalized name: EPLERENONE 50MG TAB
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive the same dose of eplerenone.
Trial: NCT03050164
Drug: Iressa® Tablet 250mg of AZN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
Trial: NCT02113293
Drug: CyclASol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A Solution
Trial: NCT02113293
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Solution
Trial: NCT02078349
Drug: KPT-330
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA \>2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
Trial: NCT03945279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03597464
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voclosporin placebo, oral, 3 capsules twice daily (BID)
Trial: NCT03192579
Drug: EPA and high dose rosuvastatin
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
Trial: NCT00120003
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
Trial: NCT03058744
Drug: IDP-118 Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT03058744
Drug: HP Monad Lotion
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: NCT00609622
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
Trial: NCT04743050
Drug: Fatty Acids, Unsaturated
RxNorm normalized name: fatty acids, unsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants from Experimental Groups will receive supplementation of different fractions of EFAs esters for six months daily. Control Group will be monitored with the same tests, but will not receive any supplementation.
Trial: NCT00825370
Drug: IV opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
Trial: NCT01708057
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8683 administered via inhalation
Trial: NCT01708057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered via inhalation
Trial: NCT03866200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml once per day for 90 days
Trial: NCT00843570
Drug: Nafarelin acetate, Oestradiol Valerate, Progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
Trial: NCT03107195
Drug: Imaging Time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to be imaged at an additional time point.
Trial: NCT00947349
Drug: BI 201335 NA low placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00947349
Drug: BI 201335 NA high placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00538681
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po, QD
Trial: NCT01798303
Drug: LY2940094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01798303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00666562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01209715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
Trial: NCT00004486
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01348737
Drug: AZD3839
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral Dose
Trial: NCT01348737
Drug: AZD3839 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Oral Dose
Trial: NCT01587950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile Water
Trial: NCT03490487
Drug: conventional antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Trial: NCT03490487
Drug: oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
Trial: NCT01665937
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen.
Trial: NCT00009737
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg/m2 iv daily from day 1 to day 5 every 28 days.
Trial: NCT00009737
Drug: Capecitabine [Xeloda]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250mg/m2 po bid on days 1-14 every 21 days.
Trial: NCT03878771
Drug: Dermovate cream in Orabase
RxNorm normalized name: benzocaine Topical Cream [Orabase]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied on oral mucositis and /or ulcer 3 times per day
Trial: NCT03426137
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
Trial: NCT00376961
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 on day 1 of cycles 1-6.
Trial: NCT00376961
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 on day 1 of cycles 1-6.
Trial: NCT00618722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02815111
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
Trial: NCT00710333
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02829034
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth twice per day for a total of 26 weeks
Trial: NCT02031679
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
Trial: NCT02031679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic AZD1981 10 mg tablet
Trial: NCT01967043
Drug: Oraxol
RxNorm normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
Trial: NCT03762967
Drug: Standard therapy.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
Trial: NCT01969721
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo/dummy for blinding purposes
Trial: NCT02493179
Drug: Serodase 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serodase 5mg two tablets three times per day
Trial: NCT02493179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo two tablets three times per day
Trial: NCT04049994
Drug: Uro-Vaxom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
Trial: NCT04049994
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT00896961
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00110305
Drug: TMC278 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 25 mg tablet will be administered once daily.
Trial: NCT00110305
Drug: TMC278 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
Trial: NCT00110305
Drug: TMC278 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
Trial: NCT00110305
Drug: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
Trial: NCT00142506
Drug: placebo tablets and questionaires
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24.
Trial: NCT00120328
Drug: SPP301
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03322800
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
Trial: NCT03572088
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
Trial: NCT00337389
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01517880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
Trial: NCT02850848
Drug: (Baraclude 0.5mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02367846
Drug: Contraceptive Vaginal Ring (CVR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
Trial: NCT01816503
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
Trial: NCT03904927
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~2. If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen.~3. Anti-PD1 antibodies plus chemotherapy could be used as first-line systemic therapy and Anti-PD1 antibodies could be used as second-line therapy.
Trial: NCT02241486
Drug: Sublingual Fentanyl Spray
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
Trial: NCT00419796
Drug: Lumiracoxib
RxNorm normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04315467
Drug: SGM-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A one-time infusion of SGM-101
Trial: NCT04279197
Drug: Fuzheng Huayu Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FZHY, administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Trial: NCT04279197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo , administration: 0.4g/tablet, 1.6g/time, 3 times/day, oral; administered half an hour after the meal.
Trial: NCT01485874
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle
Trial: NCT01830530
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two tablets daily in the morning
Trial: NCT02786069
Drug: Propionyl L-carnitine Hydrochloride
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
Trial: NCT00809133
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose cohorts
Trial: NCT01856101
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
Trial: NCT00978302
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection at time of biopsy and again 24 h later
Trial: NCT02595034
Drug: Clindamycin and Benzoyl Peroxide Gel 1%5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)